Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE3B | Q13370 | 3/20 | 0.33 |
| ▸ | PDE3A | Q14432 | 3/20 | 0.33 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.33 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.33 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.33 |
| ▸ | PI4KA | P42356 | 1/20 | 0.33 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.33 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.33 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.33 |
| ▸ | PDE2A | O00408 | 2/20 | 0.33 |
| ▸ | CDK1 | P06493 | 1/20 | 0.33 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.33 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.33 |
| ▸ | CDK2 | P24941 | 1/20 | 0.33 |
| ▸ | PDE1A | P54750 | 1/20 | 0.32 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.32 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24817958 | 0.74 | CDK4 (0.35) | ADORA2AADORA1ADORA2BPI4KAPI4K2B | |
| SCHEMBL22650902 | 0.74 | SIGMAR1 (0.34) | MEN1ALDH1A1KMT2A | |
| SCHEMBL20793348 | 0.74 | HRH3 (0.33) | ADORA2AADORA1ADORA2BPI4KAPI4K2B | |
| SCHEMBL11851419 | 0.74 | PDE2A (0.30) | PDE3BPDE3APDE2A | |
| SCHEMBL2402912 | 0.72 | DRD4 (0.41) | PDE3BPDE3APDE2APDE1APDE1B | |
| SCHEMBL17338953 | 0.72 | ADORA2A (0.32) | ADORA2AADORA1ADORA2BPI4KAPI4K2B | |
| SCHEMBL20536189 | 0.72 | MEN1 (0.43) | PDE3BPDE3AADORA2APDE2ACCNE1 | |
| SCHEMBL22604338 | 0.71 | DRD4 (0.40) | PDE3BPDE3APDE2APDE1APDE1B | |
| SCHEMBL13415333 | 0.71 | DRD4 (0.40) | PDE3BPDE3APDE2APDE1APDE1B | |
| SCHEMBL21670417 | 0.71 | CYP11B2 (0.48) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4261211-A1 | DIHYDROISOQUINOLINONE DERIVATIVE AND APPLICATION THEREOF | Etern Biopharma (Shanghai) Co., Ltd. (CN) | 2023-10-18 | — | — | EP | disclosed |
| US-20230012449-A1 | COMPOUNDS FOR THE TREATMENT OF HIV | GILEAD SCIENCES, INC. | 2023-01-12 | — | — | US | disclosed |
| WO-2022122037-A1 | DIHYDROISOQUINOLINONE DERIVATIVE AND APPLICATION THEREOF | 上海奕拓医药科技有限责任公司 | 2022-06-16 | — | — | WO | disclosed |
| US-11034668-B2 | Compounds for the treatment of HIV | GILEAD SCIENCES, INC. (US) | 2021-06-15 | — | — | US | disclosed |
| US-10391082-B2 | Protein kinase inhibitors | ORION CORPORATION (FI) | 2019-08-27 | — | — | US | disclosed |
| US-20180194746-A1 | Compounds For the Treatment of HIV | GILEAD SCIENCES, INC. | 2018-07-12 | — | — | US | disclosed |
| US-9944619-B2 | Compounds for the treatment of HIV | GILEAD SCIENCES, INC. (US) | 2018-04-17 | — | — | US | disclosed |
| US-9944619-B2 | Compounds for the treatment of HIV | GILEAD SCIENCES, INC. (US) | 2018-04-17 | — | — | US | disclosed |
| WO-2017106568-A1 | COMBINATION OF A JAK INHIBITOR AND A BROMODOMAIN INHIBITOR FOR TREATING CANCER | GILEAD SCIENCES, INC. (US) | 2017-06-22 | — | — | WO | disclosed |
| US-20170137405-A1 | COMPOUNDS FOR THE TREATMENT OF HIV | GILEAD SCIENCES, INC. | 2017-05-18 | — | — | US | disclosed |
| US-20170137405-A1 | COMPOUNDS FOR THE TREATMENT OF HIV | GILEAD SCIENCES, INC. | 2017-05-18 | — | — | US | disclosed |
| US-9540343-B2 | Compounds for the treatment of HIV | GILEAD SCIENCES, INC. (US) | 2017-01-10 | — | — | US | disclosed |
| US-20160346254-A1 | PROTEIN KINASE INHIBITORS | ORION CORP (FI) | 2016-12-01 | — | — | US | disclosed |
| US-9447091-B2 | Protein kinase inhibitors | ORION CORPORATION (FI) | 2016-09-20 | — | — | US | disclosed |
| US-20160031855-A1 | PROTEIN KINASE INHIBITORS | ORION CORPORATION (FI) | 2016-02-04 | — | — | US | disclosed |
| US-20150011548-A1 | PROTEIN KINASE INHIBITORS | AURIGENE ONCOLOGY LIMITED (IN) | 2015-01-08 | — | — | US | disclosed |
| US-20140142085-A1 | COMPOUNDS FOR THE TREATMENT OF HIV | GILEAD SCIENCES, INC. (US) | 2014-05-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150011548-A1 | PROTEIN KINASE INHIBITORS | FGFR1, FGFR3, FGFR4 | PDE3B 1827/4885PDE3A 2505/4885ADORA2A 4345/4885 |
| US-20180194746-A1 | Compounds For the Treatment of HIV | CCR5, NPC1, FURIN | PDE3B 1282/4885PDE3A 1527/4885ADORA2A 4127/4885 |
| US-20160346254-A1 | PROTEIN KINASE INHIBITORS | FGFR1, FGFR3, FGFR4 | PDE3B 1827/4885PDE3A 2505/4885ADORA2A 4345/4885 |
| US-11034668-B2 | Compounds for the treatment of HIV | CCR5, NPC1, FURIN | PDE3B 1282/4885PDE3A 1527/4885ADORA2A 4127/4885 |
| US-20160031855-A1 | PROTEIN KINASE INHIBITORS | FGFR1, FGFR2, FGFR3 | PDE3B 2645/4885PDE3A 2682/4885ADORA2A 3300/4885 |
| US-20170137405-A1 | COMPOUNDS FOR THE TREATMENT OF HIV | CCR5, NPC1, FURIN | PDE3B 1282/4885PDE3A 1527/4885ADORA2A 4127/4885 |
| US-20140142085-A1 | COMPOUNDS FOR THE TREATMENT OF HIV | CCR5, NPC1, FURIN | PDE3B 1282/4885PDE3A 1527/4885ADORA2A 4127/4885 |
| US-10391082-B2 | Protein kinase inhibitors | FGFR1, FGFR3, FGFR4 | PDE3B 1897/4885PDE3A 2551/4885ADORA2A 4349/4885 |
| US-20230012449-A1 | COMPOUNDS FOR THE TREATMENT OF HIV | CCR5, NPC1, FURIN | PDE3B 1282/4885PDE3A 1527/4885ADORA2A 4127/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.